MedTrace Logo

CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)

NCT00681122 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2600

Last updated 2016-01-18

No results posted yet for this study

Summary

This observational study is restricted to postmenopausal women with hormone-sensitive early breast cancer, who have decided to take prescribed adjuvant use of AIs, anastrozole or letrozole, according to the current product SmPCs. There is no Investigational Medicinal Product (IMP) to be taken in this observational study. The adjuvant AI medication must not have exceeded thirteen weeks. In CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily practicE through Educational approach), impact of educational material on women's compliance and persistence rates will be evaluated.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Neven, P. Prof. · KUL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Australia
  • Austria
  • Belgium
  • Chile
  • Colombia
  • Croatia
  • Czechia
  • Finland
  • France
  • Greece
  • Italy
  • Peru
  • Romania
  • Sweden
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom
  • Venezuela

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00681122 on ClinicalTrials.gov